IOSP
Innospec·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
High Cash/net Profit Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IOSP
Innospec Inc.
A manufacturer of fuel additives, personal care and fragrance products, and specialty chemicals
8310 South Valley Highway, Suite 350, Englewood, Colorado 80112
--
Innospec Inc., a Delaware corporation, was established on January 27, 1998. The company develops, manufactures, blends, markets and supplies a wide range of specialty chemicals to customers in the Americas, Europe, the Middle East, Africa and Asia Pacific. The company's high-performance chemicals business creates innovative technology-based solutions for industrial markets such as personal care, home care, agrochemicals, construction, and mining. The Company's Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, enhance engine performance and reduce harmful emissions. The company's oilfield services business provides drilling, completion and production chemicals, which make exploration and production more cost-effective and environmentally friendly.
Earnings Call
Company Financials
EPS
IOSP has released its 2025 Q3 earnings. EPS was reported at 1.12, versus the expected 1.06, beating expectations. The chart below visualizes how IOSP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IOSP has released its 2025 Q3 earnings report, with revenue of 441.90M, reflecting a YoY change of -0.34%, and net profit of 12.90M, showing a YoY change of -61.38%. The Sankey diagram below clearly presents IOSP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available


